{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:42:30Z","timestamp":1785256950027,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71874209"],"award-info":[{"award-number":["71874209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170759"],"award-info":[{"award-number":["82170759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770691"],"award-info":[{"award-number":["81770691"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073818"],"award-info":[{"award-number":["82073818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40411"],"award-info":[{"award-number":["2019JJ40411"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2022ZZTS0282"],"award-info":[{"award-number":["2022ZZTS0282"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010083","name":"Hunan Provincial Innovation Foundation for Postgraduate","doi-asserted-by":"publisher","award":["CX20220364"],"award-info":[{"award-number":["CX20220364"]}],"id":[{"id":"10.13039\/501100010083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clinthera.2023.07.014","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:23:31Z","timestamp":1690881811000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States"],"prefix":"10.1016","volume":"45","author":[{"given":"Ye","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.07.014_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2023.07.014_sbref0002","series-title":"Cancer facts & figures 2023 [Internet]","year":"2023"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658054","article-title":"Cost-Effectiveness of adding ribociclib to endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer among premenopausal or perimenopausal women","volume":"11","author":"Jeong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.014_sbref0005","series-title":"NCCN clinical practice guidelines in oncology: breast cancer. Version 2.2022 [Internet]","year":"2022"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0006","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40273-023-01245-y","article-title":"Cost effectiveness of CDK4\/6 inhibitors in the first-line treatment of HR+\/HER2- metastatic breast cancer in postmenopausal women in the USA","volume":"41","author":"Masurkar","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0009","article-title":"Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment of women with HR+\/HER2- advanced or metastatic breast cancer: a US payer perspective","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.clinthera.2019.04.033","article-title":"Cost-effectiveness analysis of adding palbociclib as a second-line endocrine therapy for HR(+)\/HER2(-) metastatic breast cancer from the US and Chinese perspectives","volume":"41","author":"Zhang","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0011","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.2147\/CMAR.S284556","article-title":"Cost-effectiveness of ribociclib for hormone receptor-positive HER2-negative advanced breast cancer","volume":"12","author":"Yang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0012","first-page":"514","article-title":"Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- advanced or metastatic breast cancer: a U.S. payer perspective","volume":"24","author":"Mistry","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0013","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","article-title":"First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a cost-effectiveness analysis","volume":"21","author":"Huang","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0014","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10549-011-1919-y","article-title":"A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer","volume":"132","author":"Montero","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/COC.0b013e31827e4e9a","article-title":"Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer","volume":"37","author":"Refaat","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0016","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3389\/fonc.2020.01336","article-title":"Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2-positive metastatic breast cancer from the US and Chinese perspectives","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0017","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2015.62.9105","article-title":"Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"34","author":"Durkee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-016-3958-x","article-title":"Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer","volume":"159","author":"Le","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-016-3978-6","article-title":"Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States","volume":"160","author":"Diaby","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14737167.2021.1848553","article-title":"Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews","volume":"21","author":"Diaby","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0021","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10198-021-01315-y","article-title":"Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis","volume":"22","author":"Grady","year":"2021","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0024","unstructured":"US Bureau of Labor Statistics. Calculators. 2022. https:\/\/www.bls.gov\/data\/inflationcalculator.htm. Accessed 10 Apr 2022."},{"key":"10.1016\/j.clinthera.2023.07.014_bib0025","unstructured":"Medicare. Medicare ASP Drug Pricing Files. [cited 2022 Aug 24] Available from: https:\/\/www.cms.gov\/files\/zip\/april-2022-asp-pricing-file.zip."},{"key":"10.1016\/j.clinthera.2023.07.014_bib0026","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0027","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0028","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.21037\/apm-21-2412","article-title":"Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China","volume":"10","author":"Wang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0029","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40261-021-01035-4","article-title":"Cost-effectiveness Analysis of trastuzumab emtansine as second-line therapy for HER2-positive breast cancer in China","volume":"41","author":"Zhang","year":"2021","journal-title":"Clinical drug investigation"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0030","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0031","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737167.1.1.37","article-title":"Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin","volume":"1","author":"Craig","year":"2001","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0033","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0034","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0035","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1007\/s12325-022-02273-4","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer in the USA","volume":"39","author":"Wang","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0036","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1001\/jama.2016.16885","article-title":"US spending on personal health care and public health, 1996-2013","volume":"316","author":"Dieleman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.07.014_bib0037","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41571-018-0027-x","article-title":"Sustainability and affordability of cancer drugs: a novel pricing model","volume":"15","author":"Uyl-de Groot","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:22:35Z","timestamp":1777490555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0149291823002643"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}